Last reviewed 2026-04-23 · How we verify

IgM-enriched IVIG

IgM-enriched IVIG provides passive immunotherapy by supplying immunoglobulin M antibodies to enhance immune response and modulate inflammatory pathways.

IgM-enriched IVIG provides passive immunotherapy by supplying immunoglobulin M antibodies to enhance immune response and modulate inflammatory pathways. Used for Immunodeficiency disorders, Sepsis and severe infections, Autoimmune and inflammatory conditions.

At a glance

Mechanism of action

IgM-enriched intravenous immunoglobulin (IVIG) is an immunoglobulin preparation with elevated IgM content that acts as a passive immunotherapeutic agent. It functions by providing pre-formed antibodies that can neutralize pathogens, enhance complement activation, and modulate immune responses through Fc receptor engagement. This formulation is designed to provide broader immune coverage compared to standard IVIG, which is predominantly IgG.

Approved indications

• Immunodeficiency disorders
• Sepsis and severe infections
• Autoimmune and inflammatory conditions

Common side effects

• Infusion reactions
• Headache
• Fever
• Thromboembolism
• Renal dysfunction

Key clinical trials

• IgM-Enriched Immunoglobulin for Neonatal Sepsis (PHASE3)
• Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients
• The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis (PHASE1)
• Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis' (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.